<DOC>
	<DOCNO>NCT00499863</DOCNO>
	<brief_summary>To assess efficacy safety efficacy MTS compare placebo</brief_summary>
	<brief_title>Evaluate Efficacy &amp; Safety Methylphenidate Transdermal System ( MTS ) Adolescents Aged 13-17 Years With ADHD</brief_title>
	<detailed_description>To assess efficacy safety efficacy MTS compare placebo , determine change clinician complete ADHD Rating Scale - Version 4th Edition ( ADHD-RS-IV ) , symptomatic treatment adolescent ( age 13-17 year ) diagnose ADHD .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>1 . Subject must meet criterion primary diagnosis ADHD base detailed psychiatric evaluation . 2 . Subject must total score â‰¥26 ADHDRSIV Baseline Visit ( Visit 2 ) . 3 . Subject must minimum level intellectual functioning , determine IQ ( base Kaufman Brief Intelligence Test [ KBIT ] ) score 80 . 4 . Subject blood pressure measurement within 95th percentile age , gender , height Screening Baseline . 5 . Subject male female age 13 17 year . 6 . Females must negative serum beta Human Chorionic Gonadotropin ( HCG ) pregnancy test Screening negative urine pregnancy test Baseline agree use acceptable contraceptive throughout study period 30 day last dose IP . 1 . Subject current , control ( require restrict medication ) uncontrolled , significant symptom Post Traumatic Stress Disorder , psychosis , bipolar illness , pervasive developmental disorder , severe obsessive compulsive disorder , severe depressive severe anxiety disorder . 2 . Subjects , opinion Investigator , acutely risk suicidal violent behavior towards him/herself others , history suicide attempt require medical intervention . 3 . Subject overweight . 4 . Subject history seizure last 2 year , tic disorder , current diagnosis and/or family history Tourette 's Disorder . 5 . Subject Conduct Disorder . 6 . Subject positive urine drug alcohol result Screening ( exception subject 's current stimulant therapy , ) . 7 . Subject history alcohol substance abuse dependence . 8 . Subject take investigational drug within 30 day prior screen . 9 . Subject abnormal thyroid function . 10 . Subject clinically significant laboratory abnormality . 11 . Subject severe allergic rhinitis , disability , condition might confound result safety assessment administer study might increase risk subject . Mild , stable asthma exclusionary . 12 . The female subject pregnant lactating . 13 . Subject skin disease , history chronic skin disease , skin cancer , skin manifestation allergic disease , dermatologic condition would interfere trial assessment compromise subject safety ( e.g . dermatitis , eczema psoriasis ) . 14 . Subject sensitiveskin syndrome ( definition : subject often develop nonspecific skin irritancy reaction bland material ) sensitivities ingredient soap , lotion , cosmetic adhesive . 15 . Subject clinical sign symptom skin irritation ( i.e. , pruritus , burning , erythema ) scar tattoos .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>